BioWorld

May 17, 2010

Pharma Outlicensing: From Opportunism to R&D Funding

A common theme heard around the hallways of the BIO 2010 International Convention earlier this month was that the big pharma firms in attendance were doing more selling than buying. Read More

Money Raised Year to Date

Savient for Sale, Ardea Bid Adds Dose: Gout on Move

German Plan: Blood in Water for Overseas Reimbursement?

Money Raised By Biotech in 2010

Week in Review

Word on the Street

FDA Approvals in April

Phase I Clinical Trials Update: April 2010

Phase II Clinical Trials Update: April 2010

Pivotal/Phase III Clinical Trials Update: April 2010

Non-U.S. Clinical Trials And Regulatory Actions: April 2010

FDA Submissions, Approvals And Other Actions: April 2010

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for Jan 21, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 20, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...